Aldeyra Therapeutics Inc. (ALDX)
5.20
-0.55 (-9.57%)
At close: Apr 01, 2025, 3:04 PM
-9.57% (1D)
| Bid | 5.19 |
| Market Cap | 310.49M |
| Revenue (ttm) | 245.45K |
| Net Income (ttm) | -56.06M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -5.53 |
| Forward PE | -15.64 |
| Analyst | Buy |
| Ask | 5.21 |
| Volume | 1,694,743 |
| Avg. Volume (20D) | 564,106 |
| Open | 5.80 |
| Previous Close | 5.75 |
| Day's Range | 5.04 - 5.91 |
| 52-Week Range | 3.10 - 7.20 |
| Beta | 1.24 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria...
Industry Biotechnology
Sector Healthcare
IPO Date May 2, 2014
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ALDX
Website https://www.aldeyra.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ALDX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 92.31% from the latest price.
Stock Forecasts4 months ago
+11.64%
Aldeyra Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
7 months ago
+28.53%
Aldeyra Therapeutics shares are trading higher after the company achieved the primary endpoint in its Phase 3 trial for Reproxalap ophthalmic solution in treating dry eye disease. The company anticipates resubmitting its NDA in 2024.
